Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY ...
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
(Reuters) -The blue-chip Dow Jones Industrial Average closed at a record high on Friday as investors welcomed a subdued ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...
Bristol Myers Squibb has received U.S. FDA approval for a new schizophrenia drug, marking the first new antipsychotic medication in decades. The drug, Cobenfy, lacks warnings about increased mortality ...
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...
The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback